Abstract
Gastroesophageal reflux disease is a common disorder in the United States and other western countries. In addition to troublesome symptoms, this condition is associated with impaired quality of life and the potential for disease progression to esophageal adenocarcinoma. Acid suppression medications are extremely effective for the relief of heartburn symptoms, but don't address the physiologic derangements that cause reflux. The goal of an antireflux procedure is to correct these defects and abolish the dietary and lifestyle compromises that accompany medical therapy for gastroesophageal reflux. The Nissen fundoplication has a long and well-established track record and new options such as the LINX magnetic sphincter augmentation device allow correction of reflux with fewer side-effects than a fundoplication in appropriate patients. These options should be considered in patients incompletely satisfied on medical therapy and in those with risk factors for disease progression. The role of these therapies in patients with gastroesophageal reflux disease will be reviewed in this chapter. Achalasia is an uncommon motility disorder of the esophagus that leads to profound dysphagia symptoms and greatly impaired alimentary satisfaction. Pneumatic dilation offers an endoscopic approach to the management of these patients, but often requires repeated dilatations due to the inconsistent disruption of the lower esophageal sphincter with this technique. An alternative is a laparoscopic Heller myotomy, which offers precise division of the muscle of the lower esophageal sphincter, but requires incisions and lifestyle restrictions while healing. A new therapy, per-oral endoscopic myotomy, allows the precise division of the lower esophageal sphincter muscle as in a laparoscopic myotomy, but is done endoscopically with no external incisions. The role of these therapies in patients will be reviewed in this chapter.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have